To this end, we investigated a panel of subtype-relevant markers, including CD44 and Olig2.27, 28, 29 Using immunohistochemical analysis, we established that pMAPK expression was heterogeneously expressed within GBM tumors and was inversely associated with CD44 expression (Figure 7c). Here, CD44 is linked to glioblastoma.